Priscilla Chan

And so the idea of being able to very specifically and accurately

with less sort of the conditioning and morbidity and mortality of the treatment, being able to address this is incredible.

And the implications for other diseases like blood cancers or other hematopoietic diseases, that's incredible.

And that actually has an incredibly broad base of patients that can benefit from the learnings from these babies with severe combined immunodeficiencies.

I just want to emphasize one point that's really exciting as we talk about these ultra rare cases that sort of, you know, they're often like one in a million.

All these learnings actually help maximize the impact of lots of research across the sector that impacts actually everyone's health.

And so our learnings here from these patients that are sort of have

very significant presentations that really can stand to benefit from any treatment is hopefully paving the way for many, many more of us to be able to live healthier, higher quality lives through basic science.